ArticleHuman gene therapy2015
Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.
Article in Human gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs.Scientific reports · 2019Pooled it
- Cytokine-Enhanced Vaccine as Surgery Adjuvant Treatment for Spontaneous Canine Melanoma: Comparison of Two Intralesional Procedures for Local Disease Control.Veterinary and comparative oncology · 2026Article
- The Suicide Gene System Cytosine Deaminase::Uracylphosphoribosyltransferase/5-fluorocytosine Displays a Strong Cytotoxic Effect on Human Melanoma Cells.Current pharmaceutical biotechnology · 2026Article
- Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024).Veterinary sciences · 2025Review
- Treatment of Canine Oral Melanomas: A Critical Review of the Literature.Veterinary sciences · 2022Review
- Particulate mediators of the bystander effect linked to suicide and interferon-β transgene expression in melanoma cells.Gene therapy · 2021Article
- Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2019Review
- Combination of cytokine-enhanced vaccine and chemo-gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.Gene therapy · 2019Article
- A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma.Veterinary sciences · 2019Review
- Canine Cancer: Strategies in Experimental Therapeutics.Frontiers in oncology · 2019Review
- Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.Clinics (Sao Paulo, Brazil) · 2018Review
- Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma.Veterinary sciences · 2018Article
- Nonviral Gene Therapy for Cancer: A Review.Diseases (Basel, Switzerland) · 2018Review
- Therapeutic potential of bleomycin plus suicide or interferon-β gene transfer combination for spontaneous feline and canine melanoma.Oncoscience · 2017Article
- Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.Veterinary and comparative oncology · 2017Article
- Recent clinical trials of cancer immunogene therapy in companion animals.World journal of experimental medicine · 2017Review
- Review
- Cross-species models of human melanoma.The Journal of pathology · 2016Review
- Clinical trials of immunogene therapy for spontaneous tumors in companion animals.TheScientificWorldJournal · 2014Review
- A Winning New Combination? Toward Clinical Application in Oncology.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present here a nonviral immunogene therapy trial for canine malignant melanoma, an aggressive disease displaying significant clinical and histopathological overlapping with human melanoma. As a surgery adjuvant approach, it comprised the co-injection of lipoplexes bearing herpes simplex virus thymidine kinase and canine interferon-β genes at the time of surgery, combined with the periodic administration of a subcutaneous genetic vaccine composed of tumor extracts and lipoplexes carrying the genes of human interleukin-2 and human granulocyte-macrophage colony-stimulating factor. Following complete surgery (CS), the combined treatment (CT) significantly raised the portion of local disease-free canine patients from 11% to 83% and distant metastases-free (M0) from 44% to 89%, as compared with surgery-only-treated controls (ST). Even after partial surgery (PS), CT better controlled the systemic disease (M0: 82%) than ST (M0: 48%). Moreover, compared with ST, CT caused a significant 7-fold (CS) and 4-fold (PS) rise of overall survival, and >17-fold (CS) and >13-fold (PS) rise of metastasis-free survival. The dramatic increase of PS metastasis-free survival (>1321 days) and CS recurrence- and metastasis-free survival (both >2251 days) demonstrated that CT was shifting a rapidly lethal disease into a chronic one. In conclusion, this surgery adjuvant CT was able of significantly delaying or preventing postsurgical recurrence and distant metastasis, increasing disease-free and overall survival, and maintaining the quality of life. The high number of canine patients involved in CT (301) and the extensive follow-up (>6 years) with minimal or absent toxicity warrant the long-term safety and efficacy of this treatment. This successful clinical outcome justifies attempting a similar scheme for human melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.